NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY -- -- First patient enrolled in RUBENS Phase 3 trial of obicetrapib and obicetrapib/ezetimibe fixed dose combo (FDC) in patients with metabolic syndrome -- -- Year-end cash, cash equivalents and marketable securities balance of approximately $729 million (unaudited) -- NAARDEN, the Netherlands and MIAMI, Jan. 09, 2 ...